CRISPR Therapeutics Announces Chief Financial Officer Transition
ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J. Silver, the Company's Senior Vice President of Finance, will succeed Dr. Prasad as Chief Financial Officer. This transition will be effective today.
Covered in this story
What has happened since
- Crispr Therapeutics AG is down 0.3% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Crispr Therapeutics AG
- Citizens JMP: $54.1 → $80 by Sep 2027 · Market Outperform via Investing.com
- Morgan Stanley: $48.4 → $60 by Jul 2027 · Equal Weight via Yahoo Finance
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CRSP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Crispr Therapeutics AG →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.